Compass Total Cash From Operating Activities from 2010 to 2024

CMPX Stock  USD 1.56  0.05  3.31%   
Compass Therapeutics Total Cash From Operating Activities yearly trend continues to be fairly stable with very little volatility. Total Cash From Operating Activities will likely drop to about -42.6 M in 2024. During the period from 2010 to 2024, Compass Therapeutics Total Cash From Operating Activities regression line of annual values had significance of  0.77 and arithmetic mean of (33,247,527). View All Fundamentals
 
Total Cash From Operating Activities  
First Reported
2018-06-30
Previous Quarter
-13.9 M
Current Value
-10.8 M
Quarterly Volatility
3.7 M
 
Covid
Check Compass Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Compass Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 8.3 M or Interest Income of 8.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.4. Compass financial statements analysis is a perfect complement when working with Compass Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Compass Therapeutics Correlation against competitors.
For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.

Latest Compass Therapeutics' Total Cash From Operating Activities Growth Pattern

Below is the plot of the Total Cash From Operating Activities of Compass Therapeutics over the last few years. It is Compass Therapeutics' Total Cash From Operating Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Compass Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Cash From Operating Activities10 Years Trend
Very volatile
   Total Cash From Operating Activities   
       Timeline  

Compass Total Cash From Operating Activities Regression Statistics

Arithmetic Mean(33,247,527)
Coefficient Of Variation(15.53)
Mean Deviation2,871,011
Median(33,679,000)
Standard Deviation5,164,540
Sample Variance26.7T
Range23M
R-Value(0.08)
Mean Square Error28.5T
R-Squared0.01
Significance0.77
Slope(93,205)
Total Sum of Squares373.4T

Compass Total Cash From Operating Activities History

2024-42.6 M
2023-40.6 M
2022-34.1 M
2021-19.7 M
2020-26.8 M
2019-31.7 M

About Compass Therapeutics Financial Statements

Compass Therapeutics investors use historical fundamental indicators, such as Compass Therapeutics' Total Cash From Operating Activities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Compass Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Cash From Operating Activities-40.6 M-42.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.